REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
285.89
+4.27 (+1.52%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close281.62
Open280.50
Bid0.00 x 800
Ask0.00 x 1000
Day's Range280.50 - 287.28
52 Week Range271.57 - 442.00
Volume476,124
Avg. Volume770,030
Market Cap31.4B
Beta (3Y Monthly)0.86
PE Ratio (TTM)15.88
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire

    U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced today that the U.S. District Court for the District of Delaware ruled in their favor and found as a matter of law that Amgen's asserted patent claims for antibodies targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) are invalid based on lack of enablement. "Today's decision by the U.S. District Court for the District of Delaware validates our position that Amgen's patents are overly broad and invalid," said Joseph LaRosa, Executive Vice President, General Counsel and Secretary, Regeneron.

  • PR Newswire

    Regeneron Announces Upcoming Investor Conference Presentation

    TARRYTOWN, N.Y. , Aug. 15, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the Morgan Stanley 17th Annual Global Healthcare Conference at 8:10 a.m. ...

  • PR Newswire

    Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol

    Regeneron Pharmaceuticals, Inc. (REGN) today announced positive pivotal Phase 3 results for evinacumab, an investigational angiopoietin-like 3 (ANGPTL3) antibody, in patients with homozygous familial hypercholesterolemia (HoFH). Patients with HoFH have severely elevated levels of bad cholesterol (otherwise known as low-density lipoprotein cholesterol, or LDL cholesterol), and often experience early atherosclerotic disease, sometimes suffering cardiac events as early as their teenage years.

  • PR Newswire

    FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe

    The 2 mg, single-dose, sterilized prefilled syringe provides physicians with a new way to administer EYLEA that requires fewer preparation steps compared to vials. Market supply of the EYLEA prefilled syringe is expected to be available to physicians and patients this year.

  • PR Newswire

    PALM Ebola Clinical Trial Stopped Early as Regeneron's REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths

    ZMapp served as the control arm of the trial because it was considered the standard-of-care based on the previous PREVAIL II clinical trial. The independent data safety monitoring board decided to stop the trial after reviewing interim mortality data from 499 patients. "The Regeneron team worked tirelessly to discover, develop and produce REGN-EB3 in record time utilizing our VelocImmune®-based technologies," said Neil Stahl, Ph.D., Executive Vice President of Research and Development at Regeneron.

  • PR Newswire

    Regeneron Reports Second Quarter 2019 Financial and Operating Results

    TARRYTOWN, N.Y. , Aug. 6, 2019 /PRNewswire/ -- -- Second quarter 2019 revenues increased 20% to $1.93 billion versus second quarter 2018 EYLEA ® U.S. net sales increased 17% to $1.16 billion versus second ...

  • PR Newswire

    Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Dermatitis

    Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that a pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints. Dupixent is the first and only biologic to show positive results in this pediatric atopic dermatitis population. In the U.S., Dupixent is currently approved in patients 12 years and older with moderate-to-severe atopic dermatitis, as well as moderate-to-severe asthma and adults with severe chronic rhinosinusitis with nasal polyposis (CRSwNP).

  • PR Newswire

    Dupixent® (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) extended marketing authorization for Dupixent® (dupilumab) in the European Union (EU) to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. Dupixent is now the first biologic medicine approved in the EU to treat these patients. "Moderate-to-severe atopic dermatitis can affect many aspects of an adolescent's life, including their physical and emotional well-being," said Christine Janus, Chief Executive Officer of the International Alliance of Dermatology Patient Organizations.

  • PR Newswire

    Regeneron Announces the 2019 Winners of the Regeneron Prize for Creative Innovation

    TARRYTOWN, N.Y., July 18, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the winners of the seventh annual Regeneron Prize for Creative Innovation. The country's leading research universities were asked to nominate top candidates for the Regeneron Prize in the 'graduate student' and 'postdoctoral fellow' categories. In total $155,000 in prize money and donations was awarded to finalists, winners and institutions.

  • PR Newswire

    Regeneron to Report Second Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on August 6, 2019

    TARRYTOWN, N.Y. , July 8, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:   REGN) today announced that it will report its second quarter 2019 financial and operating results on Tuesday, August ...

  • PR Newswire

    Libtayo® (cemiplimab) Approved for Advanced Cutaneous Squamous Cell Carcinoma in the European Union

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has granted conditional marketing authorization for Libtayo® (cemiplimab) for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. "With no other medical treatments approved for advanced CSCC in the EU, Libtayo represents an important new option for patients affected with this advanced skin cancer who cannot be cured by surgery or radiation," said Axel Hauschild, M.D., Ph.D., an investigator in the pivotal CSCC clinical program and Professor and Head of the Interdisciplinary Skin Cancer Center at the University Hospital Schleswig-Holstein in Kiel, Germany.

  • PR Newswire

    FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis

    PARIS and TARRYTOWN, N.Y., June 26, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. CRSwNP can be a debilitating condition, with many patients opting for systemic steroids or nasal surgery which often cannot control this disease.

  • PR Newswire

    FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. CRSwNP can be a debilitating condition, with many patients opting for systemic steroids or nasal surgery, which often cannot control this disease.

  • PR Newswire

    Regeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 2 proof-of-concept trial evaluating the investigational IL-33 antibody REGN3500 (SAR440340) met the primary endpoint of improvement in loss of asthma control when comparing REGN3500 monotherapy to placebo. Patients treated with Dupixent® (dupilumab) monotherapy did numerically better than REGN3500 across all endpoints, although the trial was not powered to show differences between active treatment arms. The combination of REGN3500 and Dupixent also did not demonstrate increased benefit compared to Dupixent monotherapy in this trial.

  • PR Newswire

    Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive early-stage data for REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). The emerging data, which includes patients with R/R diffuse large B-cell lymphoma (DLBCL) who had progressed after CAR-T therapy, will be presented tomorrow at the 24th Congress of the European Hematology Association (EHA). "We are very encouraged by the continued high response rates observed with REGN1979 in both relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, cancers with typically poor outcomes," said Israel Lowy, M.D., Ph.D., Senior Vice President and Head of Clinical and Translational Sciences, Oncology at Regeneron.

  • PR Newswire

    Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that positive updated data for Libtayo® (cemiplimab-rwlc) in locally advanced and metastatic cutaneous squamous cell carcinoma (CSCC) will be shared at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago. Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 (programmed cell death protein-1) and is the only treatment approved for patients with metastatic CSCC or locally advanced CSCC who are not candidates for curative surgery or curative radiation in the U.S.

  • PR Newswire

    FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy

    - EYLEA improves diabetic retinopathy and prevents worsening disease that can lead to blindness - Diabetic retinopathy is the leading cause of blindness among working-aged American adults TARRYTOWN, N.Y. ...

  • GlobeNewswire

    Sanofi : Dupixent® (dupilumab) Approved for Severe Asthma by European Commission

    May 7, 2019 - The European Commission has approved Dupixent® (dupilumab) for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroid (ICS) plus another medicinal product for maintenance treatment.

  • PR Newswire

    Dupixent® (dupilumab) Approved for Severe Asthma by European Commission

    Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the European Commission (EC) approved a new indication for Dupixent® (dupilumab) in asthma. Dupixent is now approved in the European Union (EU) for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroid (ICS) plus another medicinal product for maintenance treatment.

  • PR Newswire

    Regeneron Reports First Quarter 2019 Financial and Operating Results

    TARRYTOWN, N.Y. , May 7, 2019 /PRNewswire/ --   First quarter 2019 revenues increased 13% to $1.71 billion versus first quarter 2018 First quarter 2019 EYLEA ® (aflibercept) Injection U.S. net sales increased ...

  • PR Newswire

    Regeneron Announces Upcoming Investor Conference Presentations

    TARRYTOWN, N.Y. , April 29, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations as follows: Bank of America Merrill Lynch 2019 Healthcare Conference ...

  • GlobeNewswire

    Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization

    April 26, 2019 - The U.S. Food and Drug Administration (FDA) has approved Praluent® (alirocumab) to reduce the risk of heart attack, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular (CV) disease. "Today`s FDA approval marks a significant achievement in the treatment of adults with established cardiovascular disease, who are among those at greatest risk of death or disability caused by serious cardiovascular events," said John Reed, M.D., Ph.D., Global Head of Research & Development, Sanofi.

  • PR Newswire

    FDA Approves Praluent® (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring Hospitalization

    Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Praluent® (alirocumab) to reduce the risk of heart attack, stroke and unstable angina requiring hospitalization in adults with established cardiovascular (CV) disease. "Heart disease accounts for one quarter of all American deaths each year and many others are at risk for heart attack and stroke due to uncontrolled LDL-C levels," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer, Regeneron.